---
schema_version: "secwatch.filing_event.v1"
accession: "0001438133-24-000166"
form_type: "8-K"
ticker: "TNDM"
cik: "0001438133"
company_name: "TANDEM DIABETES CARE INC"
filed_at: "2024-06-21T23:59:59+00:00"
generated_at: "2026-06-01T02:47:04.416094+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Tandem Diabetes appoints Jean-Claude Kyrillos as EVP, COO effective June 21, 2024

## Summary
- Kyrillos previously served as President of Diagnostics & Digital Solutions at Envista Holdings and held senior roles at Qualcomm Life, BD, and ResMed.
- Annual base salary set at $450,203.73; target bonus of 60% of base salary (0-200% payout range) under Cash Bonus Plan.
- Target long-term incentive of 400% of base salary in RSUs under the 2023 Long-Term Incentive Plan.
- Severance agreement provides 18 months base salary continuation and full equity acceleration upon qualifying termination within change-of-control window.
- Kyrillos holds a BA from Colgate University and an MBA from Harvard Business School.

## SEC filing metadata
- accession: 0001438133-24-000166
- form_type: 8-K
- ticker: TNDM
- cik: 0001438133
- company_name: TANDEM DIABETES CARE INC
- filed_at: 2024-06-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438133/000143813324000166/0001438133-24-000166-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438133/000143813324000166/tndm-20240619.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438133-24-000166
- JSON: https://secwatch.observer/filing/0001438133-24-000166.json
- Plain text: https://secwatch.observer/filing/0001438133-24-000166.txt

## Key facts
- Executive change
  Jean-Claude Kyrillos was appointed as Chief Operating Officer at TANDEM DIABETES CARE INC.
  - Action: appointed
  - Role: Chief Operating Officer
  source text: On June 19, 2024, the Board of Directors of Tandem Diabetes Care, Inc. (the “Company”) approved the appointment of Jean-Claude Kyrillos as Executive Vice President, Chief Operating Officer effective June 21, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438133/000143813324000166/0001438133-24-000166-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.